Fundraising Fox

Sibylla

Trento, IT Β· 7 known investors

sibyllabiotech.it β†—

Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution. The company focuses on protein misfolding diseases, particularly prion diseases.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

EBEmiliano Biasini
Emiliano BiasiniCo-founder
PFPietro Faccioli
Pietro FaccioliCo-founder
GS
Giovanni SpagnolliCo-founder, CTO
MLMaria Letizia Barreca
Maria Letizia BarrecaCo-founder
GLGraziano Lolli
Graziano LolliCo-founder

Investors Β· 7

3B Future Health Fundβœ“ verifiedMonaco Β· $12M
CDP Venture Capitalβœ“ verifiedRome
Seroba Life Sciencesβœ“ verifiedDublin Β· $540K – $7.6M
V-Bio Venturesβœ“ verifiedGhent Β· $270K – $2.2M
Vertis SGRβœ“ verifiedNaples
VI Partnersβœ“ verifiedAltendorf Β· $2.2M – $4.5M
Claris VenturesTurin

In the news

Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform - Sibylla Biotechsibyllabiotech.it Β· Oct 2022Sibylla Biotech Raises €23M in Series A Fundingfinsmes.com Β· Oct 2022Investors - Sibylla Biotechsibyllabiotech.it Β· Jun 2021

Frequently asked questions

What does Sibylla do?
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution. The company focuses on protein misfolding diseases, particularly prion diseases.
Who founded Sibylla?
Sibylla was founded by Emiliano Biasini, Pietro Faccioli, Giovanni Spagnolli, Maria Letizia Barreca, Graziano Lolli.
Who are Sibylla's investors?
Sibylla's investors include 3B Future Health Fund, CDP Venture Capital, Seroba Life Sciences, V-Bio Ventures, Vertis SGR, VI Partners, Claris Ventures.
Where is Sibylla headquartered?
Sibylla is headquartered in Trento, IT.